<SEC-DOCUMENT>0001493152-26-036008.txt : 20260804
<SEC-HEADER>0001493152-26-036008.hdr.sgml : 20260804
<ACCEPTANCE-DATETIME>20260804163021
ACCESSION NUMBER:		0001493152-26-036008
CONFORMED SUBMISSION TYPE:	425
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260804
DATE AS OF CHANGE:		20260804

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANGOCEUTICALS, INC.
		CENTRAL INDEX KEY:			0001938046
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				873841292
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		425
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41615
		FILM NUMBER:		261239266

	BUSINESS ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
		BUSINESS PHONE:		(833) 626-4679

	MAIL ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANGOCEUTICALS, INC.
		CENTRAL INDEX KEY:			0001938046
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				873841292
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		425

	BUSINESS ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
		BUSINESS PHONE:		(833) 626-4679

	MAIL ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
</SEC-HEADER>
<DOCUMENT>
<TYPE>425
<SEQUENCE>1
<FILENAME>form425.htm
<DESCRIPTION>425
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> Filed by Mangoceuticals,
Inc. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> Pursuant to Rule 425 under
the Securities Act of 1933, as amended, </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> and deemed filed pursuant
to Rule 14a-12 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> under the Securities Exchange
Act of 1934, as amended </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> Subject Company: Nuclea
Energy Inc. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"> Commission File No.: 001-41615 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> On August 4, 2026, the
following press release was issued by Mangoceuticals, Inc., in connection with the proposed business combination contemplated by the
Business Combination Agreement described in the Current Report on Form 8-K filed by Mangoceuticals, Inc. with the Securities and Exchange
Commission on July 30, 2026. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="form425_001.jpg" ALT="" STYLE="height: 48px; width: 126px"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mangoceuticals
Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
Texas &ndash; August 4, 2026 &ndash; Mangoceuticals, Inc. (NASDAQ: MGRX) (&ldquo;Mangoceuticals&rdquo; or the &ldquo;Company&rdquo;)
today announced it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) to regain
compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2).The Company now has until February 1,
2027 to meet the requirement for its shares of common stock to maintain a closing bid price of at least US $1.00 per share for a minimum
of 10 consecutive business days. Nasdaq granted the extension after determining that Mangoceuticals meets the continued listing requirement
for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, and
following Mangoceuticals providing written notice of its intention to cure the deficiency within the extension period, if necessary,
through a reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news comes as the Company continues to advance its previously announced definitive business combination agreement with Nuclea Energy
Inc., an advanced nuclear technology company developing the Morpheus microreactor, a lead cooled, factory built micro modular reactor
designed to meet growing demand for reliable, carbon free power from AI infrastructure, data centers, and other applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
D. Cohen, Chief Executive Officer of Mangoceuticals, commented: &ldquo;We appreciate Nasdaq&rsquo;s decision to grant this extension,
which provides Mangoceuticals with continued flexibility as we advance our operational and strategic objectives with Nuclea Energy representing
a transformative opportunity. We further look forward to bringing meaningful value to shareholders through exposure to the advanced nuclear
sector and the commercialization potential of the Morpheus microreactor. We will continue to provide the market with further updates
as they develop, and we thank our shareholders for their continued patience and support.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company remains committed to full compliance with all Nasdaq listing requirements and will continue to monitor its share price closely.
Mangoceuticals plans to take all necessary actions within the prescribed period to regain compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Mangoceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MangoRx
is focused on developing a variety of men&rsquo;s health and wellness products and services via a secure telemedicine platform. To date,
the Company currently offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth,
hormone replacement therapies, and weight management. Interested consumers can use MangoRx&rsquo;s telemedicine platform for a smooth
experience. Prescription requests will be reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped
through MangoRx&rsquo;s partner compounding pharmacy and right to the patient&rsquo;s doorstep. To learn more about MangoRx&rsquo;s mission
and other products, please visit <U>www.MangoRx.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the proposed transaction, Mangoceuticals intends to file relevant materials with the SEC, including a registration statement
containing a proxy statement in connection with the stockholder approval described above. INVESTORS AND SECURITY HOLDERS ARE URGED TO
READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE,
AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free
copies of these documents through the website maintained by the SEC at <U>www.sec.gov</U>, or by directing a request to Mangoceuticals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants
in the Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
Nuclea and their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed
to be participants in the solicitation of proxies from Mangoceuticals&rsquo; stockholders in connection with the transaction. Investors
and security holders may obtain more detailed information regarding the names, affiliations and interests of Mangoceuticals&rsquo; executive
officers and directors in its most recent Annual Report on Form 10-K and other filings with the SEC. Additional information regarding
the persons who may be deemed participants in the solicitation and their interests will be set forth in the proxy statement and other
relevant materials when they become available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Offer or Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any
securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the
proposed transaction and its expected structure, timing and completion; the anticipated ownership percentages of Mangoceuticals following
closing; the anticipated benefits of the transaction to Mangoceuticals&rsquo; stockholders; projected electricity demand; and the development,
licensing, commercialization and performance of the Morpheus microreactor, which remains in the conceptual design stage. Forward-looking
statements are based on current expectations and assumptions and are subject to significant risks and uncertainties, including the risk
that the transaction may not be completed on the anticipated terms or timing, or at all; the ability to obtain required regulatory, Nasdaq
and stockholder approvals; the ability to obtain nuclear licensing approvals; the availability of capital; and technology development
risks. Actual results may differ materially from those expressed or implied. Neither Mangoceuticals nor Nuclea undertakes any obligation
to update forward-looking statements except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
INVESTOR RELATIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals
Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>investors@mangorx.com</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form425_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form425_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !W AD# 2(  A$! Q$!_\0
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MU/4-.C3'BS2O"DC".@#]?**B$A/ 7<2S+\C!@HY*,Y.TJ'4 \*V"<9(P3+0
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MCCN_^%TINAMS9?:/.\O#+*(\ IO? _XC&O\ @EI_T3']M/\ \-'\,_\ Y]U
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ME9E5@!-(V^;RXTP4F=./WFUX5A4<_=^T'_>K_0G^&?\ P9<?LVZ;I5@OQ?\
MVU_C[XMU2*(/=6W@'P/\-OA]HJN1EHULM7MOB).X7IO-\H)'"D<GN?%W_!F'
M^Q3J&GW$/@C]K3]JOPMJ$D/EV\GB%?ACXUT6V;_GI_8J>$/#$TG^[_:\?LU
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MFL]4UO2;N47WC6\4CYQ<+% '\+L-OF&U8-,$!-PT2)$OZ)_\%#_C)>?"_P"
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M(D3<@90%2.<$AW*\XR>I)[DFBXF>.152,$-Y#-D[0B3@'<#WV^F.?4=#]I?
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M^&;.UM[6&_E^P!6U'6M6OK2"VEU#7?$]TOV[Q-J;A+K6+R2>>[E=YB5_R?\
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M;);%U$LZZ7X8U#4X@DP>>RM+XN($MS)+_E8T >T?LT_\G+?LW_\ 9P7P&_\
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MBB@#^'?_ (/7O^25_P#!/'_LJWQZ_P#4+\ 5_ /7]_'_  >O?\DK_P"">/\
MV5;X]?\ J%^ *_@'H _HO_X-5'S_ ,%F?A-Q_P T+_:&/7T\((?2O]5&O\JO
M_@U3_P"4S/PF_P"R%_M#_P#J'I7^JI0 4444 ?R6?\'BG_*,SX0?]G@_#/\
M]5I\7J_S4J_TK?\ @\4_Y1F?"#_L\'X9_P#JM/B]7^:E0!^Q'_!OW_RF5_8)
M_P"RJ>*?_59>/J_U^*_R!_\ @W[_ .4RO[!/_95/%/\ ZK+Q]7^OQ0 4444
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MN/LVBZS<E4#W?A^^N(H4N8MRLWE2[)1G@L.%_G7&&'(_/^=-,9*E20ZXP/,
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MT/K_ #?XZ_3&XO\ %O+,TX*RG)\MX5X4Q5+"8?.HX;%3X@S7/Z&!JPJ4*?\
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MZEQ(3EPK*'(W/MDV>=&&<MLBE,4+&.(1 -&&!ST /\,K_A3_ ,8O^B/?%O\
M\-?X^_\ F<K^G?\ X-+? 'Q \*?\%5/$>J>)_A_X]\,:8?V3OBK81:EXH\%>
M*/#-A+/>^-OA-)%"+S7-)L+<7!AM;N6.W61VF%NXB9OF*_Z8'DC^^W_?$/\
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M)X^.S/-<T=\US;-LTEK[V9YKF.835]TI8S&8B44^T7%#EMF'!D0J%*JODJH
M(Q@[6&Y0.BGC'%/6 J#\R9(P"(@N/KAOF'L?3K117J3IPJ05.<>9*SBY.]2,
MTG%58U7>I&LDW:M&2JW=^>YQ?:4E>+5_=@^2#OI>5./+";\Y1;\RQ1115@%%
E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
